Key result
Sarpogrelate treatment inhibited platelet aggregation dose-dependently in patients with ischemic stroke (p < 0.025), with 100 mg showing greater effect than 25 mg or 50 mg.
Why the study?
Does sarpogrelate dose-dependently inhibit platelet aggregation in patients with ischemic stroke?
Population
47 patients with ischemic stroke
Comparison
Sarpogrelate 50 mg or 100 mg orally three times… vs Sarpogrelate 25 mg orally three times daily for…
Design
RCT, randomly assigned, double-blind
Follow-up
7 days
Authors
Loading...
100 mg TID yields superior platelet inhibition in ischemic stroke; confirms dose-dependency and informs dosing for outcome trials.
RCT (n=47)
Double-blind
randomly assigned
Does sarpogrelate dose-dependently inhibit platelet aggregation in patients with ischemic stroke?
p-value: p=<0.025
Sarpogrelate dose-dependently inhibits platelet aggregation in patients with ischemic stroke, with 100 mg TID showing superior efficacy to lower doses.
Uchiyama et al. (2007) conducted an RCT in Ischemic stroke (n=47). Sarpogrelate vs. Lower doses (25 mg or 50 mg) was evaluated on Maximum intensity of platelet aggregation on the last day of medication (p=<0.025). Sarpogrelate treatment inhibited platelet aggregation dose-dependently in patients with ischemic stroke (p < 0.025), with 100 mg showing greater effect than 25 mg or 50 mg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: